1. Home
  2. HWH vs APRE Comparison

HWH vs APRE Comparison

Compare HWH & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HWH
  • APRE
  • Stock Information
  • Founded
  • HWH 2021
  • APRE 2006
  • Country
  • HWH United States
  • APRE United States
  • Employees
  • HWH N/A
  • APRE N/A
  • Industry
  • HWH Other Pharmaceuticals
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • HWH Health Care
  • APRE Health Care
  • Exchange
  • HWH Nasdaq
  • APRE Nasdaq
  • Market Cap
  • HWH 8.5M
  • APRE 10.0M
  • IPO Year
  • HWH N/A
  • APRE 2019
  • Fundamental
  • Price
  • HWH $1.30
  • APRE $1.74
  • Analyst Decision
  • HWH
  • APRE Strong Buy
  • Analyst Count
  • HWH 0
  • APRE 2
  • Target Price
  • HWH N/A
  • APRE $15.50
  • AVG Volume (30 Days)
  • HWH 44.8K
  • APRE 55.2K
  • Earning Date
  • HWH 08-11-2025
  • APRE 08-11-2025
  • Dividend Yield
  • HWH N/A
  • APRE N/A
  • EPS Growth
  • HWH N/A
  • APRE N/A
  • EPS
  • HWH N/A
  • APRE N/A
  • Revenue
  • HWH $1,262,664.00
  • APRE $1,284,475.00
  • Revenue This Year
  • HWH N/A
  • APRE N/A
  • Revenue Next Year
  • HWH N/A
  • APRE N/A
  • P/E Ratio
  • HWH N/A
  • APRE N/A
  • Revenue Growth
  • HWH 37.84
  • APRE 33.27
  • 52 Week Low
  • HWH $0.90
  • APRE $1.41
  • 52 Week High
  • HWH $7.20
  • APRE $5.01
  • Technical
  • Relative Strength Index (RSI)
  • HWH 47.36
  • APRE 52.83
  • Support Level
  • HWH $1.35
  • APRE $1.70
  • Resistance Level
  • HWH $1.47
  • APRE $1.97
  • Average True Range (ATR)
  • HWH 0.10
  • APRE 0.17
  • MACD
  • HWH 0.00
  • APRE 0.01
  • Stochastic Oscillator
  • HWH 42.69
  • APRE 65.44

About HWH HWH International Inc.

HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Share on Social Networks: